timothy sykes logo
Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure Thumbnail
ADD US ONG Google News

Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure

JACK KELLOGG•UPDATED MAR. 9, 2026, 10:19 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

UniQure N.V. stocks have been trading up by 17.03 percent as promising FDA designations boost investor confidence.

Candlestick Chart

Live Update At 10:19:30 EST: On Monday, March 09, 2026 uniQure N.V. stock [NASDAQ: QURE] is trending up by 17.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

In recent financial snapshots, uniQure demonstrated both challenges and successes. For the fiscal year 2025, the company reported a narrower net loss of $3.46 per share compared to the prior $4.92. However, it still experienced a drop in revenue, declining to $16M from the preceding year’s $27.1M. During this period, an improvement in earnings per share came just as analyst expectations anticipated more significant losses. Despite weaker revenue, uniQure painted a brighter picture of its 36-month data for AMT-130, which has shown positive efficacy against Huntington’s disease. Concurrently, the FDA’s caution casts a cloud of uncertainty above approval timelines.

QURE’s recent stock behavior shows a turbulent landscape. Throughout several days, the stock wavered significantly. For instance, it opened at $18.015 on Mar 9, 2026, and closed at $16.74. These fluctuations capture the market’s reaction to uniQure’s earnings report and looming regulatory hurdles. Several analysts decided to adjust their target prices, stemming from both positive and negative analyst perceptions. Stifel, for example, slashed the price target from $40 to $14, yet maintained a buy recommendation. This reflects a dichotomy in investor sentiment, with the stock seemingly set to navigate uncertain waters as FDA decisions loom large.

Market Reactions to Recent Developments

The recent discourse from Leerink casts an illuminating perspective on uniQure’s 25% stock dive. This selloff was likely an overshot response to what participants thought were FDA commentaries aimed at AMT-130. Upon deeper investigation, comments seemingly targeted another therapy by Regenxbio. Against this backdrop, uncertainties surrounding uniQure were exacerbated by FDA official Dr. Vinay Prasad’s resignation. Prasad, known for rejecting critical applications like uniQure’s Huntington’s drug, leaves behind an impression of easing tensions for big pharmaceutical companies.

The resignation ignites possibilities for uniQure. Now, a more favorable rapport with regulators seems within reach, opening discussions for path alignment which have stalled thus far. Enhanced dialogue post-Prasad could usher in promising prospects for AMT-130’s regulatory clearance. Meanwhile, RBC Capital stays optimistic, reaffirming an Outperform rating for uniQure with a $45 price target. Though criticized on CNBC, uniQure’s rare-disease approach hasn’t drawn formal negative action, indicating room for strategic negotiation.

Insight from H.C. Wainwright suggests that the potential requirement for a sham-surgery Phase 3 trial may not be set in stone. Given the robust data already available for AMT-130, there’s an undercurrent of hope that uniQure may skirt this intricate path, opting instead for a less cumbersome route towards FDA approval. Despite grim optics following FDA feedback, analysts maintain that uniQure still presents a viable investment avenue, hinting that investor pessimism might be misplaced.

More Breaking News

Conclusion

Ultimately, uniQure’s journey is marked by volatility, fueled by a blend of external regulatory pressures and internal innovations. Recent market moves can be viewed as knee-jerk reactions, grounded more in perceived threats than in uniQure’s robust underlying data. While regulatory hurdles remain formidable, the exit of scrutinous FDA figures like Dr. Prasad usher in new possibilities—heralding regulatory leniency and renewed interest from traders. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” These sentiments are reflected across recent downgrades in price targets yet sustained buy ratings, suggesting that uniQure’s narrative may be gearing up for reframed trader discourse, rekindling enthusiasm for another bout in the biotech race.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading QURE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”